What the LUNAR trial tested SAN FRANCISCO, September 28, 2025 — A new phase II clinical trial, called LUNAR, shows that adding a radiopharmaceutical drug before high-precision radiation therapy can help people with a limited number of metastatic lesions from recurrent prostate cancer live longer without disease progression. In this randomized study, patients received either…